PMID: 25743838Mar 7, 2015Paper

Hypermethylation of promoter region of LATS1--a CDK interacting protein in oral squamous cell carcinomas--a pilot study in India

Asian Pacific Journal of Cancer Prevention : APJCP
Vijaya Ramakrishna ReddyArvind Ramanathan

Abstract

Epigenetic silencing of tumor suppressor genes due to promoter hypermethylation is one of the frequent mechanisms observed in cancers. Hypermethylation of several tumor suppressor genes involved in cell cycle regulation has been reported in many types of tumors including oral squamous cell carcinomas. LATS1 (Large Tumor Suppressor, isoform 1) is a novel tumor suppressor gene that regulates cell cycle progression by forming complexes with the cyclin dependent kinase, CDK1. Promoter hypermethylation of the LATS1 gene has been observed in several carcinomas and also has been linked with prognosis. However, the methylation status of LATS1 in oral squamous cell carcinomas is not known. As oral cancer is one of the most prevalent forms of cancer in India, the present study was designed to investigate the methylation status of LATS1 promoter and associate it with histopathological findings in order to determine any associations of the genetic status with stage of differentiation. Tumor chromosomal DNA isolated from biopsy tissues of thirteen oral squamous cell carcinoma biopsy tissues were subjected to digestion with methylation sensitive HpaII enzyme followed by amplification with primers flanking CCGG motifs in promoter region of LA...Continue Reading

References

Oct 16, 2002·Laboratory Investigation; a Journal of Technical Methods and Pathology·Masanori HisaokaHiroshi Hashimoto
Aug 3, 2005·Cancer Research·John BothosThanos D Halazonetis
Dec 13, 2006·Journal of Cancer Research and Clinical Oncology·Frank ChristophKurt Miller
Dec 26, 2007·The Journal of Biological Chemistry·Yawei HaoXiaolong Yang
Sep 3, 2010·BMC Medical Genetics·Haiwang YangDacheng Tian
Oct 12, 2010·Cell Cycle·Stacy Visser, Xiaolong Yang
Dec 22, 2010·Journal of the National Cancer Institute·Céline VallotFrançois Radvanyi
Feb 15, 2011·Current Opinion in Genetics & Development·Yael Aylon, Moshe Oren
Sep 14, 2013·Cancer Cell·Sara Koenig McLaughlinKaren Cichowski
Feb 13, 2014·Journal of Cellular Physiology·Katarzyna M Marcinkiewicz, Lorraine J Gudas
Feb 27, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Anupam Mishra, Rohit Meherotra
Apr 10, 2014·Cell Adhesion & Migration·Alan S Mak
Jun 28, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Dhaval Tushar MehtaArvind Ramanathan
Aug 2, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Hai LinDong Lin
Aug 30, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Sarika SharmaArun Gupta
Dec 7, 2014·Molecular Cell·Tomer Cooks, Curtis C Harris

❮ Previous
Next ❯

Citations

Jun 24, 2017·Cell Death and Differentiation·Noa Furth, Yael Aylon
May 16, 2017·Oncology Reports·Agnieszka RybarczykPiotr M Wierzbicki
May 2, 2018·Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology·Nikolaos G NikitakisJohn J Sauk

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.